It was a pleasure to meet with Prof. Eric Daar (Harbor-UCLA Medical Center, West Carson, CA, USA) to the challenges posed by metabolic comorbidities in people with HIV. Part 2 of this interview can be found here.
The abstract entitled: ‘Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
Questions:
- Could you give us a brief overview of the challenges posed by metabolic comorbidities to the long-term care of people with HIV? (0:16)
Disclosures: Eric Daar is a consultant for Gilead and Merck, and receives research support from Gilead, Merck and ViiV Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
